Emerging evidence does not support the use of HCQ for treatment or prevention of SARS -CoV2 infection. No pts have been enrolled.

This study is being done to see if hydroxychloroquine is an effective treatment for COVID-19.

Inclusion Criteria:

• Age 18 years and older
• Subjects must have a documented positive test for the SARS-CoV-2 infection within 7 days of randomization
• Subject must be hospitalized within 72 hours of randomization
• Subjects must be receiving standard of care for SARS-CoV-2
• Subject/Legally Authorized Representative (LAR) must have the ability to understand and give informed consent
• Subject must be able to take and absorb hydroxychloroquine at the discretion of the investigator

Exclusion Criteria:

• Prior receipt of hydroxychloroquine for treatment or prophylaxis of SARS-CoV-2 or patient is taking hydroxychloroquine for other approved indications (e.g., lupus, rheumatoid arthritis)
• No documented SARS-CoV-2 infection
• Mechanical ventilation
• Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives Preexisting retinopathy documented in medical history
• Pregnancy or Breastfeeding
• Concurrent use of any other quinine derivative (chloroquine, mefloquine) or rifamycins (rifampin, rifabutin)
• Antiarrhythmic medications (amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide)
• History of glucose-6-phosphate dehydrogenase deficiency
• Pre-treatment corrected QT interval (QTc) >500 milliseconds
• Pressor requirement to maintain blood pressure
• Alanine aminotransferase (ALT) and/or asparate aminotransferase (AST) level > 5X upper limit of normal
• Creatinine clearance <30 mL/min or requirement of dialysis or continuous venovenous hemofiltration
• Concomitant participation in a therapeutic trial for SARS-CoV-2 or receiving any experimental treatment for SARS-CoV-2 within 7 days of randomization
• Any condition that in the opinion of the principal investigator would prevent participation in the trial or would interfere with the trial endpoints

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.